Cilgavimab/Tixagevimab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.

**Synonyms:** - AZD 7442 - AZD-7442 - AZD7442 - AZD8895 + AZD1061 - AZD8895/AZD1061 - Anti-SARS-CoV-2 Spike Protein Monoclonal Antibody AZD7442 - Evusheld - Monoclonal Antibody AZD7442 - Monoclonal antibodies against SARS-CoV-2: tixagevimab/cilgavimab